ADOCIA Confirms Its Eligibility for the PEA - PME

LYON, France--()--Regulatory News:

ADOCIA (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC) confirms its eligibility for the “PEA – PME” stock savings tax regime, which decree has been published in the French Journal Officiel on March 4, 2014 (Decree n ° 2014-283), and which entered into force on March 6, 2014.

To be eligible for the “PEA – PME”, the shares must have been issued by a company whose market capitalization is below one billion euros, of which no legal person holds more than 25% of its capital, which has less than 5,000 employees, and an annual turnover not exceeding 1 500 million euros or a total balance sheet less than 2 000 million euros.

Adocia meets all of these conditions.

About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia’s clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500).
In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro programs.

Adocia’s extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaborations programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn® nanotechnology platform.

Adocia aims to deliver “Innovative medicine for everyone, everywhere.”

To learn more about Adocia, please visit us at www.adocia.com

Contacts

Adocia
Gérard Soula, Tél. : +33 4 72 610 610
Chairman and CEO
contactinvestisseurs@adocia.com
or
Adocia Press Relations France
ALIZE RP
Caroline Carmagnol et Florence Portejoie, Tél. : + 33 1 44 54 36 61
caroline@alizerp.com
adocia@alizerp.com
or
Adocia Press Relations Europe
MC Services AG
Raimund Gabriel, Tél. : +49 89 210 228 0
raimund.gabriel@mc-services.eu
adocia@mc-services.eu

Contacts

Adocia
Gérard Soula, Tél. : +33 4 72 610 610
Chairman and CEO
contactinvestisseurs@adocia.com
or
Adocia Press Relations France
ALIZE RP
Caroline Carmagnol et Florence Portejoie, Tél. : + 33 1 44 54 36 61
caroline@alizerp.com
adocia@alizerp.com
or
Adocia Press Relations Europe
MC Services AG
Raimund Gabriel, Tél. : +49 89 210 228 0
raimund.gabriel@mc-services.eu
adocia@mc-services.eu